Skip to main content
Fig. 6 | Orphanet Journal of Rare Diseases

Fig. 6

From: An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study

Fig. 6

NT-proBNP over time by patient. Dashed line, cardiac involvement; solid line, no cardiac involvement. Patients with values below the lower limit of quantification (< X) or above the upper limit of quantification (> X) have been plotted as values of X. AA, serum amyloid A; ApoAI, apolipoprotein A-I; AFib, fibrinogen-a alpha chain; AL, immunoglobulin light chain; ATTR, transthyretin; NT-proBNP, N-terminal-pro B-type natriuretic peptide

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172